Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus.

Ryo SuzukiJun-Ichi EikiTakashi MoritoyoKenichi FurihataAkira WakanaYukari OhtaShigeru TokitaTakashi Kadowaki

Published in: Diabetes, obesity & metabolism (2018)

This study suggests that the DPP4 inhibitor sitagliptin has a greater ability to reduce daily glucose fluctuation than the SU glibenclamide in drug-naïve Japanese patients with T2DM. ClinicalTrials.gov: NCT02318693.

Keyphrases

physical activity
blood glucose
adverse drug
drug induced
emergency department
metabolic syndrome
glycemic control
weight loss